Crotamiton

Evidence Level: L5

Predicted Indications: 10

Crotamiton
Crotamiton: From Scabies to Trombiculiasis

## Pharmacist Assessment Report

Using no additional skill — this is a direct report-generation task with a fully specified template; I’ll follow the prompt’s instructions and the evidence pack as given.

A few notes on how I handled data gaps (per the prohibitions — no literal “[Data Gap]” in output):

original_indications and original_moa are empty/gap in the pack, but the evidence pack’s own rationale text repeatedly references Crotamiton’s established use as a scabicide/antipruritic — I’ve used that as background context, flagged as not sourced from formal MOA data.
taiwan_regulatory.licenses is empty (drug not marketed in the UK), so the UK Market Information table is omitted entirely per the “no empty sections” rule, replaced with a short note.
All ranks 2–10 are flagged by the pack itself as likely graph noise (no plausible mechanism) — only rank 1 (trombiculiasis) is reported, per template scope.

Crotamiton: From Scabies to Trombiculiasis

One-Sentence Summary

Crotamiton is an established topical scabicide and antipruritic agent, traditionally used to treat scabies (Sarcoptes scabiei infestation) and its associated itching. The TxGNN model predicts it may also be effective for Trombiculiasis (chigger/harvest mite bite dermatitis), but this prediction is currently supported by no registered clinical trials and no published literature — it is a computational hypothesis only.

Quick Overview

Item	Content
Original Indication	Scabies (established pharmacological use; not confirmed via formal UK licensing data in this evidence pack)
Predicted New Indication	Trombiculiasis (chigger/harvest mite bite dermatitis)
TxGNN Prediction Score	96.24%
Evidence Level	L5 (model prediction only, no supporting studies)
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available for Crotamiton in this evidence pack. Based on known pharmacological information, Crotamiton is a topical agent with established scabicidal and antipruritic activity, used clinically for scabies infestation and the itching that accompanies it. Its precise mechanism against arthropod ectoparasites has not been fully elucidated, but it is known to have direct activity against mite infestations and the pruritus they cause.

Trombiculiasis is a dermatological condition caused by the bite of chigger (trombiculid) mites, producing intense localised itching and skin inflammation — mechanistically closely related to scabies, which is also caused by a burrowing mite (Sarcoptes scabiei). Given that Crotamiton is already active against one arthropod ectoparasite and its associated pruritus, extrapolation to another mite-related dermatosis is biologically plausible.

However, plausibility is not evidence: no clinical trials or published literature currently exist testing Crotamiton specifically in trombiculiasis, so this remains a hypothesis generated purely from the knowledge graph, not a validated therapeutic claim.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

UK Market Information

Crotamiton currently holds no MHRA marketing authorisations and is not marketed in the UK according to this evidence pack. Formal SmPC/BNF entries and licensing status should be independently verified before any further evaluation.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction sits at Evidence Level L5 with no clinical trials, no published literature, and no UK marketing authorisation to support it — it is a research hypothesis generated by the TxGNN model, not a validated repurposing candidate. The mechanistic rationale (mite-associated pruritus) is plausible but entirely unconfirmed.

To proceed, the following is needed:

Formal mechanism of action (MOA) data from DrugBank or SmPC sources
UK/MHRA licensing and market status verification
Safety data: key warnings, contraindications, and drug interaction profile
Preclinical or case-level evidence specifically addressing trombiculiasis before any clinical investigation is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.